CapMan announced today that it has signed an agreement to sell its ownership of CapMan Procurement S...
We lower adjusted EBITA by 2-4% for 2024E-26E ahead of Elanders' Q3 2024 report.
Redeye gives a comment on today’s news that IRLAB has successfully completed the first part of the p...
Analyst Group har med MoveByBike ingått avtal om kontinuerlig analysbevakning, innefattande bl.
IRLAB Therapeutics has announced an encouraging update for the ongoing Phase I trial for IRL757, whi...
Yesterday (2 October), Ferronordic hosted its 2024 CMD.
Redeye provides a short research update following the outcome of the TO3 warrants recently published...
Analyst Group har med Umida Group ingått avtal om kontinuerlig analysbevakning, innefattande bl.
Last night, Climeon announced a directed share issue of SEK50m adding about a year of runway in our ...
Cereno Scientific has reported positive top-line results for the Phase IIa CS1-003 trial, which eval...
Odinwell står inför en betydande marknadsmöjlighet inom sårvård med sin innovativa teknologi.
TCECUR Sweden AB (”TCECUR” eller ”Koncernen”) meddelade den 1 oktober 2024 att Sectragon Internation...
New targets ahead of CMD at 13:00 CET 14% 5Y sales CAGR, 6% EBIT margin,
Redeye comments on the two announcements about receiving USD6.
Redeye endorses the news that Egetis has finalized a directed issue of some SEK300m to new and exist...
IRLAB Therapeutics has announced the completion of patient enrolment for the Phase IIb trial (React ...
Duell publishes its Q4 (6-8/24) figures on Wednesday 9th of October.
Redeye comments briefly on the appointment of Philippe Cohen as new CEO while we leave our estimates...
Redeye updates its estimates for the Q3 2024 report (due 2024-10-25).
Redeye expects Smart Eye's Q3, due 14 November, to show a 21% y/y sales growth, EBITDA of SEK -19m, ...
